

Coding and Billing Guide

for PADCEV® (enfortumab vedotin-ejfv)

BOXED WARNING: SERIOUS SKIN REACTIONS

- PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.
- Closely monitor patients for skin reactions.
- Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.
- Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.

Indication

PADCEV, in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).

PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who:

- have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
- are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.




Table of Contents

lr	ntroduction
R	elevant Billing Codes for PADC
	Healthcare Common Procedure Co
	National Drug Code (NDC)
	Current Procedural Terminology® (Service
	International Classification of Disea (ICD-10-CM) Diagnosis Codes

Sample Claim Form

Physician Office CMS-1500 Claim

Outpatient Hospital CMS-1450 (U

PADCEV Support Solutions14

PLEASE SEE IMPORTANT SAFETY INFORMATION ON PAGES 16-21. PLEASE CLICK HERE FOR FULL PRESCRIBING INFORMATION, **INCLUDING BOXED WARNING.**

4
CEV® (enfortumab vedotin-ejfv)
oding System (HCPCS)6
7
(CPT [®]) Codes for Drug Administration 7
eases, 10 th Revision, Clinical Modification 8

Form	10
B-04) Claim Form	12
	1 /





Introduction

Accurate and appropriate coding and billing can help avoid delays in claims processing and facilitate timely reimbursement. Astellas and Seagen are providing this guide as an educational reference, providing general coding and billing information to facilitate medically appropriate patient access to PADCEV[®] (enfortumab vedotin-ejfv).

This guide is offered for informational purposes only and is not intended to provide reimbursement or legal advice. Each healthcare provider is responsible for determining the appropriate codes, coverage, and payment for individual patients. Astellas and Seagen do not guarantee third-party coverage or payment or reimbursement for denied claims.

Because insurance coverage, coding, claims filing, and reimbursement vary by setting of care as well as by payer type, the information included in this guide is general. Healthcare providers should always verify coverage prior to initiating therapy and determine the appropriate codes on a case-by-case basis.

While Astellas and Seagen have made every effort to be current as of the publication of this guide, the information may not be as current when you view it. Similarly, all Current Procedural Terminology® (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes are supplied for informational purposes only. This information does not represent any statement, promise, or guarantee by Astellas and Seagen about coverage, levels of reimbursement, payment, or charge. Additional information may exist, and actual coverage and reimbursement decisions are made by individual payers. Providers should contact the applicable third-party payers for specific information on coding and billing requirements.

Avoiding Denied Claims

Understanding the reasons why medical claims may be denied by insurers can help limit the number of denials. Potential causes of delayed or denied claims may include:

- Invalid or missing codes (CPT, J-code, International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM])
- Incorrect product information
- Missing or incorrect National Drug Code (NDC), prior authorization number, National Provider Identifier
- Incorrect patient identifier information (eg, insurance identification number, date of birth)
- Failure to follow payer-specific requirements

Reminders for Submitting Claims

The following reminders may help when submitting claims for PADCEV:

- Determine if PADCEV is covered as a medical or pharmacy benefit prior to infusion and if there are any applicable prior authorization requirements
- Accurately complete and submit the prior authorization form, if required
- **Ensure medical records include full and proper** documentation of the patient's history, prior therapy, and rationale for treatment to justify coding
- Specify the correct number of billing units on the CMS-1500 Claim Form or on the UB-04/CMS-1450 Claim Form. Dosing for PADCEV is weight-based. Therefore, ensure the actual dose administered to the patient is reflected in the billing units (see pages 10 and 12 for instructions on filling out claim forms)

If you have questions or need assistance with benefits investigation, prior authorization, denial appeals, or coding and billing for PADCEV, please visit **PADCEVSupportSolutions.com** or call PADCEV Support Solutions at 1-888-402-0627, Monday-Friday, 8:30 AM-8:00 PM ET.

IMPORTANT INFORMATION: The coding, coverage, and payment information contained herein is gathered from various resources, general in nature, and subject to change without notice. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims conforming to the requirements of the relevant payer for those products and services rendered. Pharmacies (or any other provider submitting a claim) should contact third-party payers for specific information on their coding, coverage, and payment policies. Information and materials provided by PADCEV Support Solutions are to assist providers, but the responsibility to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure remains at all times with the provider and information provided by PADCEV Support Solutions, Astellas, or Seagen should in no way be considered a guarantee of coverage or reimbursement for any product or service.

PLEASE SEE IMPORTANT SAFETY INFORMATION ON PAGES 16-21. PLEASE CLICK HERE FOR FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

	If required, include a Letter of Medical Necessity that provides the patient's medical history and rationale for the therapy
	Verify that all identification numbers and names are entered correctly
ý,	Use the correct ICD-10-CM, CPT, and HCPCS codes, including modifiers if applicable
	Verify the proper use of billing codes
C	For the hospital outpatient setting, confirm that the correct revenue code is used with the appropriate supporting HCPCS code
5	Submit the claim in a timely fashion
	Track clearinghouse claims to ensure successful transmission



Relevant Billing Codes for PADCEV® (enfortumab vedotin-ejfv)

The billing codes listed below may be appropriate when billing for PADCEV and its administration for the treatment of the FDA-approved indication.

It is the healthcare provider's responsibility to determine the appropriate codes and to submit accurate claims for products and services provided. Astellas and Seagen do not guarantee coverage and/or reimbursement for PADCEV. Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Healthcare providers should verify coverage, coding, and reimbursement guidelines on a case-by-case basis.

Healthcare Common Procedure Coding System (HCPCS)

The HCPCS is used to identify products, supplies, and services that are billed to private and government payers by hospitals, physicians, and other healthcare professionals.

HCPCS	Description	Billing	Payers and Settings
Code ¹		Unit	of Care
J9177	Injection, enfortumab vedotin-ejfv, 0.25 mg	0.25 mg = 1 billing unit	Most payers (eg, commercial, Medicare, and Medicaid) and care settings (eg, hospital outpatient and physician office)

One billing unit of J9177 equals 0.25 mg of enfortumab vedotin-ejfv. As a result, 80 units equals 1 single-dose 20-mg vial and 120 units equals 1 single-dose 30-mg vial. Actual units reported will vary by dosage required for each individual patient.

National Drug Code (NDC)

You may be required to include an NDC for PADCEV on a claim form. The 11-digit NDCs are listed below.

NDC for PADCEV ²	
51144-0020-01	20 mg s
51144-0030-01	30 mg s

Note that the product's NDC has been "zero-filled" to ensure creation of an 11-digit code that meets Health Insurance Portability and Accountability Act (HIPAA) standards.³ The 11-digit NDC is to be preceded by the qualifier "N4" for payers that require it. This is typically followed by the quantity qualifier and the quantity administered.⁴

Current Procedural Terminology® (CPT®) Codes for Drug Administration Service

The appropriate CPT[®] code for the administration of PADCEV will depend on the actual service performed.

CPT®ª Code⁵	
96413	Chemotherapy up to 1 hour, s
96415	Chemotherap additional hou

Healthcare providers should consult the current CPT[®] manual and always select the code that accurately describes the administration service performed for the patient. Healthcare providers should also contact the payer for additional coding information required.

Description

solution in a single-dose vial for intravenous infusion

solution in a single-dose vial for intravenous infusion

Description

y administration, intravenous infusion technique, single or initial substance/drug

y administration, intravenous infusion technique, each ur (list separately in addition to code for primary procedure)

This guide is offered for informational purposes only and is not intended to provide reimbursement or legal advice. Each healthcare provider is responsible for determining the appropriate codes, coverage, and payment for individual patients.



International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes

ICD-10-CM codes are used to identify a patient's diagnosis. At least 1 ICD-10-CM diagnosis code must be included in all hospital and physician office claims to describe the patient's condition.

Metastatic Urothelial Cancer ⁶ ICD-10-CM Codes	Code Description
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter
C66.9	Malignant neoplasm of unspecified ureter
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder

Metastatic Urothelial Cancer⁵ ICD-10-CM Codes
C67.2
C67.3
C67.4
C67.5
C67.6
C67.8
C67.9
C68.0
C68.8

The ICD-10-CM diagnosis codes listed above are provided only as examples of potentially relevant codes. Providers should consult a current ICD-10-CM manual and select the most appropriate diagnosis code(s) to accurately describe a patient's condition. All diagnosis codes should be supported with adequate documentation.

Code Description

Malignant neoplasm of lateral wall of bladder

Malignant neoplasm of anterior wall of bladder

Malignant neoplasm of posterior wall of bladder

Malignant neoplasm of bladder neck

Malignant neoplasm of ureteric orifice

Malignant neoplasm of overlapping sites of bladder

Malignant neoplasm of bladder, unspecified

Malignant neoplasm of urethra

Malignant neoplasm of overlapping sites of urinary organs

This guide is offered for informational purposes only and is not intended to provide reimbursement or legal advice. Each healthcare provider is responsible for determining the appropriate codes, coverage, and payment for individual patients.



Sample Claim Form

Physician Office CMS-1500 Claim Form⁷

HEALTH INSURANCE CLAIM FORM	
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12	19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)
PICA PICA PICA	A IS. ADDITIONAL CLAIMING CHIMATION (Designated by NOCC)
[Medicare#] (Medicaid#) (ID#/DoD#) (Member ID#) (ID#) 2. PATIENT'S NAME (Last Name, First Name, Middle Initial) 3. PATIENT'S BITH DATE SEX 4. INSURED'S NAME (Last Name, First Name, Middle Initial)	21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E)
MM DD YY 5. PATIENT'S ADDRESS (No., Street) 6. PATIENT RELATIONSHIP TO INSURED 7. INSURED'S ADDRESS (No., Street)	B A. L B. L C. L
Self Spouse Child Other	
CITY STATE & RESERVED FOR NUCC USE CITY STATE	I J K 24. A. DATE(S) OF SERVICE B. C. D. PROCEDURES, SERVICES,
ZIP CODE TELEPHONE (Include Area Code)	From To PLACEOF (Explain Unusual Circumsta MM DD YY MM DD YY SERVICE EMG CPT/HCPCS MC
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) 10. IS PATIENT'S CONDITION RELATED TO: 11. INSURED'S POLICY GROUP OR FECA NUMBER	
a. OTHER INSURED'S POLICY OR GROUP NUMBER a. EMPLOYMENT? (Current or Previous)	
	2
b. RESERVED FOR NUCC USE b. AUTO ACCIDENT? PLACE (State) b. OTHER CLAIM ID (Designated by NUCC)	
C. RESERVED FOR NUCC USE C. OTHER ACCIDENT? C. INSURANCE PLAN NAME OR PROGRAM NAME	
d. INSURANCE PLAN NAME OR PROGRAM NAME 10d. CLAIM CODE® (Designated by NUCC) d. IS THERE ANOTHER HEALTH BENEFIT PLAN?	
YES NO If yes, complete items 9, 9a, and 9d. READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM. 13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize	
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.	5
SIGNED DATE SIGNED Y	
14. DATE OF CURRENT ILLNESS; INJURY, or PREGNANCY (LMP) 15. OTHER DATE UNABLE TO WORK IN CURRENT OCCUPATION AM DD YY MM DD YY MN DD YY MN DD YY MM DD YY MN	
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. 18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES MM DD YY TO DD YY TO DD YY	25. FEDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO.
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) 20. OUTSIDE LAB? \$ CHARGES	
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind. 22. RESUBUISSION OPENMAL REF. NO	
	A Item 19
	Some payers may require drug name, total
24. A DATE(S) OF SERVICE B. C. D. PROCEDURES, SERVICES, OR SUPPLIES E. F. D.	dosage, and method of administration to be
	provided in Item 19.8
2	
	B Item 21
	Enter appropriate site-specific ICD-10-CM
4 NPI	diagnosis code(s) based on the patient's
5	documented medical record. ⁴
6 NP1	
25. FEDERAL TAX J.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCOUNT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. Revd for NUCC Use	C Item 24A and 24B
31. SIGNATURE OF PHYSICIAN OF SUPPLIER 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()	Enter the date of service and the appropriate
INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereol.)	place of service code. In the red shaded area,
	enter the NDC qualifier "N4" followed by the
SIGNED DATE a. PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)	11-digit NDC, the quantity qualifier, and the
	quantity administered. ⁴

This sample form is provided for informational purposes only. The accurate completion of claims documentation is the responsibility of the healthcare provider. Astellas and Seagen do not guarantee reimbursement for any services or product.

	20. OUTSIDE LAB?	\$ CHARGES	
	YES	NO	
ICD Ind.	22. RESUBMISSION CODE	ORIGINAL REF. NO.	
D. [H. [Е	23. PRIOR AUTHORIZ		
	E.		7
DIAGNO DIFIER POINT	SIS	G. H. I. J. DAYS EPSOT ID. RENDERING UNITS Plan QUAL PROVIDER ID. #	PHYSICIAN OR SUPPLIER INFORMATION
			MA
		NPI	Ë.
			Z
		NPI	£
			2
		NPI	5
			с С
		NPI	o z
1 1			CIA
		NPI	JS (
			H
27 ACCEPT ASSIGNMEN	? 28. TOTAL CHARGE	29. AMOUNT PAID 30. Rsvd for NUCC Use	1
27. ACCEPT ASSIGNMEN	- Lot to the offende		



D Item 24D

Enter the appropriate HCPCS code for PADCEV® (enfortumab vedotin-ejfv): J9177.¹ Enter the appropriate CPT® code for the administration service.⁴ If applicable, discarded product should be reported on a separate line with the HCPCS code and JW modifier. Effective July 1, 2023, the JZ modifier is required for all single-dose containers where there are no discarded drug amounts.⁹



E Item 24E


Enter the diagnosis code reference letter or number from Item 21 that relates to the product or procedure listed in Item 24D.⁴



F Item 24G

Report billing units here. 0.25 mg = 1 billing unit. Actual units reported will vary by dosage required for each individual patient.1





This sample form is provided for informational purposes only. The accurate completion of claims documentation is the responsibility of the healthcare provider. Astellas and Seagen do not guarantee reimbursement for any services or product.

PLEASE SEE IMPORTANT SAFETY INFORMATION ON PAGES 16-21. PLEASE CLICK HERE FOR FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

12

		E				
CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49	
						1
						2
						3
						4
						5



Item 44

Enter the appropriate HCPCS code for PADCEV® (enfortumab vedotin-ejfv): J9177.1 If applicable, discarded product should be reported on a separate line with the HCPCS code and JW modifier. Effective July 1, 2023, the JZ modifier is required for all single-dose containers where there are no discarded drug amounts.9



Item 45

Enter the date of service.¹¹



E Item 46

Report billing units here. 0.25 mg = 1 billing unit.Actual units reported will vary by dosage required for each individual patient.1

	E			F	G					68	
	N			0	Р		(Q			
1 PPS CODE			72 ECI	a	b		C		73		
OCEDURE 75 DATE 75				76 ATTENDING	NPI	NPI					
				LAST				FIRST			
OCEDUR	E ATE			77 OPERATING	NPI			QUAL			
				LAST	·			FIRST			
				78 OTHER	NPI			QUAL			
		LAST	LAST				FIRST				
				79 OTHER	NPI			QUAL			
				LAST					FIRST		
C ^{1*} National Ur Billing Com	niform mittee LIC9213	3257		THE CERTIFICATION	ONS ON THE REVER	SE AP	PLY TO TH	HIS BILL A	ND A	RE MADE A PART HEREOF.	



G Item 67A-67Q

patient's treatment.11

Enter the site-specific ICD-10-CM diagnosis

codes for the malignancy being treated as documented in the patient's medical records. Other diagnosis codes are required when other

conditions coexist or develop during the

H Item 80

Some payers may require additional information such as the date the drug was furnished to the beneficiary and 11-digit NDC to be entered in Item 80.⁹ Requirements vary by payer.



PADCEV Support Solutions

PADCEV Support Solutions offers access and reimbursement support to help patients access PADCEV® (enfortumab vedotin-ejfv). PADCEV Support Solutions provides information regarding patient health coverage, financial assistance information that may be available to help patients with financial needs, and coding and billing information for PADCEV.





- Benefits investigation
- Prior authorization assistance
- Appeals assistance

_	
—	

Coding and Billing



Patient Assistance

- Copay Assistance Program^a
- Patient Assistance Program^a
- Financial assistance information



Patient Support

References

- 1. Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions (07-01-2020). https://www.cms.gov/files/document/2020-hcpcs-application summary-quarter-1-2020-drugs-and-biologicals-updated-04142020.pdf. Accessed 12-07-2023.
- 2. PADCEV [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
- PADCE V [package insert]. Not this ook, it: Asterias Finance OS, inc.
 U.S. Food and Drug Administration. National Drug Code database background information (03-20-2017). https://www.fda.gov/drugs/ develoment-approval-process-drugs/national-drug-code-database-background-information. Accessed 12-07-2023.

- Accessed 12-07-2023.
- Centers for Medicare & Medicaid Services. Billing and coding guidelines for drugs and biologics (non-chemotherapy) (04-01-2018). https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/34741_55/BCG_L34741.pdf. Accessed 12-07-2023.
- 11. Centers for Medicare & Medicaid Services. Medicare claims processing manual chapter 25 completing and processing the form CMS-1450 data
- set (08-06-2021). https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c25.pdf. Accessed 12-07-2023.

^aProgram is subject to eligibility restrictions and Program terms and conditions.

PLEASE SEE IMPORTANT SAFETY INFORMATION ON PAGES 16-21. PLEASE CLICK HERE FOR FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

Coding and billing information

Appeals information

• Patient Connect

 Geveloment-approval-process-or ugs/national-or ug-code-catabase-background-information. Accessed 12-07-2023.
 Centers for Medicare & Medicaid Services. Medicare claims processing manual chapter 26 – completing and processing form CMS-1500 data set (05-27-2022). https://www.cms.gov/Regulations-and-Guidance/Guidance/Guidance/Manuals/downloads/clm104c26.pdf. Accessed 12-07-2023.
 American Medical Association. CPT® 2023 Professional Edition. Chicago, IL: American Medical Association; 2022. American Medical Association, CP1° 2023 Professional Educin Criticago, IL: American Medical Association, 2022.
 Conters for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries (06-29-2023). https://ftp.cdc.gov/pub/Health_ Statistics/NCHS/Publications/ICD10CM/2023/icd10cm-Tabular-Index-2023.zip. Accessed 12-07-2023.
 Centers for Medicare & Medicaid Services. CMS forms. https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/Downloads/CMS1500.pdf.

9. Centers for Medicare & Medicaid Services. Medicare claims processing manual chapter 17 – drugs and biologicals (06-02-2023). https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c17.pdf. Accessed 12-07-2023. 10. National Uniform Billing Committee. Form CMS-1450. https://lni.wa.gov/forms-publications/f245-367-000.pdf. Accessed 12-07-2023.



BOXED WARNING: SERIOUS SKIN REACTIONS

- PADCEV[®] (enfortumab vedotin-ejfv) can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.
- Closely monitor patients for skin reactions.
- Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.
- Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.

Indication

PADCEV, in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).

PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who:

- have previously received a programmed death receptor-1 (PD-1) or programmed deathligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
- are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

Important Safety Information

Warnings and Precautions

Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later. Skin reactions occurred in 70% (all grades) of the 564 patients treated with PADCEV in combination with pembrolizumab in clinical trials. When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate compared to PADCEV as a single agent. The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash. Grade 3-4 skin reactions occurred in 17% of patients (Grade 3: 16%, Grade 4: 1%), including maculo-papular rash, bullous dermatitis, dermatitis, exfoliative dermatitis, pemphigoid, rash, erythematous rash, macular rash, and papular rash. A fatal reaction of bullous dermatitis occurred in one patient (0.2%). The median time to onset of severe skin reactions was 1.7 months (range: 0.1 to 17.2 months). Skin reactions led to discontinuation of PADCEV in 6% of patients.

Skin reactions occurred in 58% (all grades) of the 720 patients treated with PADCEV as a single agent in clinical trials. Twenty-three percent (23%) of patients had maculo-papular rash and 34% had pruritus. Grade 3-4 skin reactions occurred in 14% of patients, including maculo-papular rash, erythematous rash, rash or drug eruption, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, and palmar-plantar erythrodysesthesia. The median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 8 months). Among patients experiencing a skin reaction leading to dose interruption who then restarted PADCEV (n=75), 24% of patients restarting at the same dose and 24% of patients restarting at a reduced dose experienced recurrent severe skin reactions. Skin reactions led to discontinuation of PADCEV in 3.1% of patients.

Monitor patients closely throughout treatment for skin reactions. Consider topical corticosteroids and antihistamines, as clinically indicated. For persistent or recurrent Grade 2 skin reactions, consider withholding PADCEV until Grade ≤1. Withhold PADCEV and refer for specialized care for suspected SJS, TEN or for Grade 3 skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.

Hyperglycemia and diabetic ketoacidosis (DKA), including fatal events, occurred in patients with and without pre-existing diabetes mellitus, treated with PADCEV. Patients with baseline hemoglobin A1C \geq 8% were excluded from clinical trials. In clinical trials of PADCEV as a single agent, 17% of the 720 patients treated with PADCEV developed hyperglycemia of any grade; 7% of patients developed Grade 3-4 hyperglycemia (Grade 3: 6.5%, Grade 4: 0.6%). Fatal events of hyperglycemia and DKA occurred in one patient each (0.1%). The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. The median time to onset of hyperglycemia was 0.5 months (range: 0 to 20 months). Hyperglycemia led to discontinuation of PADCEV in 0.7% of patients. Five percent (5%) of patients required initiation of insulin therapy for treatment of hyperglycemia. Of the patients who initiated insulin therapy for treatment of hyperglycemia, 66% (23/35) discontinued insulin at the time of last evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.

Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ ILD occurred in patients treated with PADCEV. When PADCEV was given in combination with pembrolizumab, 10% of the 564 patients treated with combination therapy had pneumonitis/ILD of any grade and 4% had Grade 3-4. A fatal event of pneumonitis/ILD occurred in two patients (0.4%). The incidence of pneumonitis/ILD, including severe events, occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of any grade pneumonitis/ ILD was 4 months (range: 0.3 to 26 months).

In clinical trials of PADCEV as a single agent, 3% of the 720 patients treated with PADCEV had pneumonitis/ILD of any grade and 0.8% had Grade 3-4. The median time to onset of any grade pneumonitis/ILD was 2.9 months (range: 0.6 to 6 months).



Important Safety Information (continued)

Monitor patients for signs and symptoms indicative of pneumonitis/ILD such as hypoxia, cough, dyspnea or interstitial infiltrates on radiologic exams. Evaluate and exclude infectious, neoplastic and other causes for such signs and symptoms through appropriate investigations. Withhold PADCEV[®] (enfortumab vedotin-ejfv) for patients who develop Grade 2 pneumonitis/ILD and consider dose reduction. Permanently discontinue PADCEV in all patients with Grade 3 or 4 pneumonitis/ILD.

Peripheral neuropathy (PN) When PADCEV was given in combination with pembrolizumab, 67% of the 564 patients treated with combination therapy had PN of any grade, 36% had Grade 2 neuropathy, and 7% had Grade 3 neuropathy. The incidence of PN occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of Grade \geq 2 PN was 6 months (range: 0.3 to 25 months).

PN occurred in 53% of the 720 patients treated with PADCEV as a single agent in clinical trials including 38% with sensory neuropathy, 8% with muscular weakness and 7% with motor neuropathy. Thirty percent of patients experienced Grade 2 reactions and 5% experienced Grade 3-4 reactions. PN occurred in patients treated with PADCEV with or without preexisting PN. The median time to onset of Grade \geq 2 PN was 4.9 months (range: 0.1 to 20 months). Neuropathy led to treatment discontinuation in 6% of patients.

Monitor patients for symptoms of new or worsening PN and consider dose interruption or dose reduction of PADCEV when PN occurs. Permanently discontinue PADCEV in patients who develop Grade \geq 3 PN.

Ocular disorders were reported in 40% of the 384 patients treated with PADCEV as a single agent in clinical trials in which ophthalmologic exams were scheduled. The majority of these events involved the cornea and included events associated with dry eye such as keratitis, blurred vision, increased lacrimation, conjunctivitis, limbal stem cell deficiency, and keratopathy. Dry eye symptoms occurred in 30% of patients, and blurred vision occurred in 10% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.7 months (range: 0 to 30.6 months). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders.

Infusion site extravasation Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 720 patients treated with PADCEV as a single agent in clinical trials, 1% of patients experienced skin and soft tissue reactions, including 0.3% who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (0.3%) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.

Embryo-fetal toxicity PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose.

Adverse Reactions

Most common adverse reactions, including laboratory abnormalities (≥20%) (PADCEV in combination with pembrolizumab) Increased aspartate aminotransferase (AST), increased creatinine, rash, increased glucose, PN, increased lipase, decreased lymphocytes, increased alanine aminotransferase (ALT), decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection and decreased platelets.

Most common adverse reactions, including laboratory abnormalities (≥20%) (PADCEV monotherapy) Increased glucose, increased AST, decreased lymphocytes, increased creatinine, rash, fatigue, PN, decreased albumin, decreased hemoglobin, alopecia, decreased appetite, decreased neutrophils, decreased sodium, increased ALT, decreased phosphate, diarrhea, nausea, pruritus, increased urate, dry eye, dysgeusia, constipation, increased lipase, decreased weight, decreased platelets, abdominal pain, dry skin.

EV-302 Study: 440 patients with previously untreated la/mUC (PADCEV in combination with pembrolizumab)

Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab. The most common serious adverse reactions ($\geq 2\%$) were rash (6%), acute kidney injury (5%), pneumonitis/ILD (4.5%), urinary tract infection (3.6%), diarrhea (3.2%), pneumonia (2.3%), pyrexia (2%), and hyperglycemia (2%). Fatal adverse reactions occurred in 3.9% of patients treated with PADCEV in combination with pembrolizumab including acute respiratory failure (0.7%), pneumonia (0.5%), and pneumonitis/ILD (0.2%).

Adverse reactions leading to discontinuation of PADCEV occurred in 35% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were PN (15%), rash (4.1%) and pneumonitis/ILD (2.3%). Adverse reactions leading to dose interruption of PADCEV occurred in 73% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were PN (22%), rash (16%), COVID-19 (10%), diarrhea (5%), pneumonitis/ILD (4.8%), fatigue (3.9%), hyperglycemia (3.6%), increased ALT (3%) and pruritus (2.5%). Adverse reactions leading to dose reduction of PADCEV occurred in 42% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were rash (16%), PN (13%) and fatigue (2.7%).

18



EV-103 Study: 121 patients with previously untreated la/mUC who were not eligible for cisplatin-containing chemotherapy (PADCEV[®] (enfortumab vedotin-ejfv) in combination with pembrolizumab)

Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab; the most common ($\geq 2\%$) were acute kidney injury (7%), urinary tract infection (7%), urosepsis (5%), sepsis (3.3%), pneumonia (3.3%), hematuria (3.3%), pneumonitis/ILD (3.3%), urinary retention (2.5%), diarrhea (2.5%), myasthenia gravis (2.5%), myositis (2.5%), anemia (2.5%), and hypotension (2.5%). Fatal adverse reactions occurred in 5% of patients treated with PADCEV in combination with pembrolizumab, including sepsis (1.6%), bullous dermatitis (0.8%), myasthenia gravis (0.8%), and pneumonitis/ILD (0.8%). Adverse reactions leading to discontinuation of PADCEV occurred in 36% of patients; the most common (\geq 2%) were PN (20%) and rash (6%). Adverse reactions leading to dose interruption of PADCEV occurred in 69% of patients; the most common ($\geq 2\%$) were PN (18%), rash (12%), increased lipase (6%), pneumonitis/ILD (6%), diarrhea (4.1%), acute kidney injury (3.3%), increased ALT (3.3%), fatigue (3.3%), neutropenia (3.3%), urinary tract infection (3.3%), increased amylase (2.5%), anemia (2.5%), COVID-19 (2.5%), hyperglycemia (2.5%), and hypotension (2.5%). Adverse reactions leading to dose reduction of PADCEV occurred in 45% of patients; the most common ($\geq 2\%$) were PN (17%), rash (12%), fatigue (5%), neutropenia (5%), and diarrhea (4.1%).

EV-301 Study: 296 patients previously treated with a PD-1/L1 inhibitor and platinumbased chemotherapy (PADCEV monotherapy)

Serious adverse reactions occurred in 47% of patients treated with PADCEV; the most common (\geq 2%) were urinary tract infection, acute kidney injury (7% each), and pneumonia (5%). Fatal adverse reactions occurred in 3% of patients, including multiorgan dysfunction (1%), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis/ILD, and pelvic abscess (0.3% each). Adverse reactions leading to discontinuation occurred in 17% of patients; the most common (\geq 2%) were PN (5%) and rash (4%). Adverse reactions leading to dose interruption occurred in 61% of patients; the most common (\geq 4%) were PN (23%), rash (11%), and fatigue (9%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common (\geq 2%) were PN (10%), rash (8%), decreased appetite, and fatigue (3% each).

EV-201, Cohort 2 Study: 89 patients previously treated with a PD-1/L1 inhibitor and not eligible for cisplatin-based chemotherapy (PADCEV monotherapy)

Serious adverse reactions occurred in 39% of patients treated with PADCEV; the most common (\geq 3%) were pneumonia, sepsis, and diarrhea (5% each). Fatal adverse reactions occurred in 8% of patients, including acute kidney injury (2.2%), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia, and pneumonitis/ILD (1.1% each). Adverse reactions leading to discontinuation occurred in 20% of patients; the most common (\geq 2%) was PN (7%). Adverse reactions leading to dose interruption occurred in 60% of patients; the most common (\geq 3%) were PN (19%), rash (9%), fatigue (8%), diarrhea (5%), increased AST, and hyperglycemia (3% each). Adverse reactions leading to dose reduction occurred in 49% of patients; the most common (\geq 3%) were PN (19%), rash (11%), rash (11%), and fatigue (7%).

Drug Interactions

Effects of other drugs on PADCEV (Dual P-gp and Strong CYP3A4 Inhibitors)

Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated monomethyl auristatin E exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.

Specific Populations

Lactation Advise lactating women not to breastfeed during treatment with PADCEV and for 3 weeks after the last dose.

Hepatic impairment Avoid the use of PADCEV in patients with moderate or severe hepatic impairment.

20



Contact PADCEV Support Solutions[™]

There are 3 ways to contact PADCEV Support Solutions for assistance



PLEASE SEE IMPORTANT SAFETY INFORMATION ON PAGES 16-20. PLEASE <u>CLICK HERE</u> FOR FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.



PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc. Astellas® and the flying star logo are registered trademarks of Astellas Pharma Inc. Seagen® and the Seagen logo are registered trademarks of Seagen Inc. PADCEV Support Solutions^{5M}, a component of Astellas Pharma Support Solutions^{5M}, is a service mark jointly owned by Agensys, Inc., and Seagen Inc. All other trademarks or registered trademarks are the property of their respective owners.

©2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. MAT-US-PAD-2023-00217 12/23